Skip to search formSkip to main contentSkip to account menu

APC 8015

Known as: APC-8015, APC8015, APC8015 Vaccine 
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… 
National Institutes of Health

Related topics

Related topics

3 relations
Dendritic CellsProvenge

Broader (1)

sipuleucel-T

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor in fi ltration between paired primary lesions and brain metastases in lung cancer
responses to MAGE-3 protein in lung cancer patients. J Immunol 2004; 172: 3289–3296. 12. Vansteenkiste J, Cho B, Vanakesa T et al… 
Review
2011
Review
2011
Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Importance of the field: Prostate cancer is the leading malignancy in North American men and despite improvements in treatments… 
Review
2008
Review
2008
Sipuleucel-T for the treatment of prostate cancer.
Patients with cancer have deficiencies in the number and function of dendritic cells. Loaded dendritic cell therapies attempt to… 
2007
2007
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer: Small EJ, Schellhammer PF, Higano…
Review
2006
Review
2006
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
Review
2006
Review
2006
New molecular targets in advanced prostate cancer
Classically, advanced prostate cancer has been treated with hormonal therapy and, most recently, chemotherapy. This treatment… 
Highly Cited
2005
Highly Cited
2005
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
BACKGROUND Antigen-presenting cells 8015 (APC8015; Provenge) is an immunotherapeutic product designed to initiate a T-cell… 
2005
2005
1018: Immunotherapy (APC8015) for Androgen Dependent, Biochemically-Relapsed Prostate Cancer
2003
2003
Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for patients with hormone-refractory prostate cancer with a Gleason score <or= 7.
2003
2003
Autologous Dendritic Cells Pulsed with Prostatic Acid Phosphatase (APC8015) for Patients with Hormone- Refractory Prostate Cancer with a Gleason Score ≤ 7
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)